Literature DB >> 25669438

Risk factors for subclinical inflammation in children with Familial Mediterranean fever.

Meral Torun Bayram1, Tufan Çankaya, Elçin Bora, Salih Kavukçu, Ayfer Ülgenalp, Alper Soylu, Mehmet Türkmen.   

Abstract

Familial Mediterranean fever (FMF) is the most common autosomal recessive inherited inflammatory disease characterized by attacks of painful inflammation. Some patients with FMF have subclinical inflammation persisting between the attacks. We aimed to identify the demographic, clinical and genetic risk factors for subclinical inflammation in children with FMF. The medical records of the children with FMF were evaluated retrospectively for acute-phase response along with gender, age at the onset of symptoms and at the time of diagnosis, clinical signs and symptoms, the presence of amyloidosis and MEFV genotype. Patients with persistently elevated acute-phase response between the attacks were considered to have subclinical inflammation. Patients with or without subclinical inflammation (Group 1 and Group 2, respectively) were compared for the parameters defined above. Independent risk factors for subclinical inflammation were identified by multivariate logistic regression analysis. There were 105 children (male/female: 52/53) who were compliant on colchicine treatment. Subclinical inflammation was detected in 22 (20 %) patients. Group 1 had significantly higher rate of myalgia, arthritis/arthralgia, erysipelas like erythema, amyloidosis, protracted febrile myalgia and M694V mutation compared with Group 2. However, only the presence of myalgia and erysipelas like erythema were found to be independent risk factors for subclinical inflammation (OR 9.8 and 5.9, respectively). Children with FMF who have myalgia and erysipelas like erythema during the attacks are particularly at risk of ongoing inflammation and should be closely monitored for subclinical inflammation even during attack-free periods.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25669438     DOI: 10.1007/s00296-015-3227-z

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  Acute phase response and evolution of familial Mediterranean fever.

Authors:  M Tunca; G Kirkali; M Soytürk; S Akar; M B Pepys; P N Hawkins
Journal:  Lancet       Date:  1999-04-24       Impact factor: 79.321

2.  Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations.

Authors:  Dimitri Tchernitchko; Marie Legendre; Andrée Delahaye; Cécile Cazeneuve; Florence Niel; Michel Goossens; Serge Amselem; Emmanuelle Girodon
Journal:  Clin Chem       Date:  2003-11       Impact factor: 8.327

3.  Letter: Colchicine in familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; J Gafni
Journal:  N Engl J Med       Date:  1976-01-15       Impact factor: 91.245

4.  The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever.

Authors:  Ruth Gershoni-Baruch; Riva Brik; Nurit Zacks; Maruan Shinawi; Merav Lidar; Avi Livneh
Journal:  Arthritis Rheum       Date:  2003-04

5.  Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium.

Authors: 
Journal:  Cell       Date:  1997-08-22       Impact factor: 41.582

6.  Criteria for the diagnosis of familial Mediterranean fever.

Authors:  A Livneh; P Langevitz; D Zemer; N Zaks; S Kees; T Lidar; A Migdal; S Padeh; M Pras
Journal:  Arthritis Rheum       Date:  1997-10

7.  Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever.

Authors:  D Zemer; M Pras; E Sohar; M Modan; S Cabili; J Gafni
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

8.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever.

Authors:  A Duzova; A Bakkaloglu; N Besbas; R Topaloglu; S Ozen; F Ozaltin; Y Bassoy; E Yilmaz
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

9.  A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever.

Authors:  Yackov Berkun; Shai Padeh; Brian Reichman; Nurit Zaks; Einat Rabinovich; Merav Lidar; Bracha Shainberg; Avi Livneh
Journal:  Semin Arthritis Rheum       Date:  2007-05-23       Impact factor: 5.532

10.  Male sex coupled with articular manifestations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean fever homozygous for the M694V-MEFV mutation.

Authors:  Ruth Gershoni-Baruch; Riva Brik; Merav Lidar; Marwan Shinawi; Avi Livneh
Journal:  J Rheumatol       Date:  2003-02       Impact factor: 4.666

View more
  6 in total

1.  Familial Mediterranean fever in childhood: a single-center experience.

Authors:  Kenan Barut; Sezgin Sahin; Amra Adrovic; Ada Bulut Sinoplu; Gozde Yucel; Gizem Pamuk; Aslı Kirectepe Aydın; Selcuk Dasdemir; Eda Tahir Turanlı; Nur Buyru; Ozgur Kasapcopur
Journal:  Rheumatol Int       Date:  2017-08-21       Impact factor: 2.631

2.  Comorbidities and phenotype-genotype correlation in children with familial Mediterranean fever.

Authors:  Nuray Aktay Ayaz; Ayşe Tanatar; Şerife Gül Karadağ; Mustafa Çakan; Gonca Keskindemirci; Hafize Emine Sönmez
Journal:  Rheumatol Int       Date:  2020-04-28       Impact factor: 2.631

3.  Can RDW be used as a screening test for subclinical inflammation in children with FMF? Is RDW related to MEFV gene mutations?

Authors:  Gönül Parmaksız; Z Aytül Noyan
Journal:  Clin Rheumatol       Date:  2022-09-14       Impact factor: 3.650

4.  The Relationship Among the Level of Serum Amyloid A, High-Density Lipoprotein and Microalbuminuria in Patients With Familial Mediterranean Fever.

Authors:  Ali Ugur Uslu; Bahattin Aydin; Ibrahim Serhat Icagasıoğlu; Sevket Balta; Köksal Deveci; Filiz Alkan; Gürsel Yıldız; Ali Sahin
Journal:  J Clin Lab Anal       Date:  2016-04-19       Impact factor: 2.352

5.  Evaluation of S100A12 protein levels in children with familial Mediterranean fever

Authors:  Yelda Türkmenoğlu; Elif Güney; Diğdem Bezen; Ahmet İrdem; Biray Ertürk; Hasan Dursun
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

6.  [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

Authors:  T Sahr; U Kiltz; C Weseloh; T Kallinich; J Braun
Journal:  Z Rheumatol       Date:  2020-09-30       Impact factor: 1.372

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.